Novogen - Raging buy, page-3

re: Novogen - Price targets In the states the shares closed at $4.60 which is equal to $1.67 in NRT shares.

The volume was high and we should see some positive press over the next few days. The coming report should also deliver positive comments regarding Promensil sales and clinical trial developments.

Companies in the states recently announced that their anti-cancer drugs do not work which is a major positive for Novogen

This along with booming Promensil sales (due to the recent HRT scare) would make Novogen a very attractive takeover target. Its only work around $150 at these prices which is peanuts in the biotech world.

My targets is its recent high and then around the $10 mark or 1bn market cap. The markets are in a bad shape at the moment but I think even now investors will start to realise Novogens potential.

I own, and bought more today.

Cheers,
Munch.